Scorpius Launches First cGMP Mammalian Manufacturing Campaign in Q3 2024

The integrated contract development and manufacturing organisation (CDMMO) Scorpius Holdings, Inc, also known as "Scorpius" or the "Company," announced today that it plans to begin its first cGMP mammalian manufacturing campaign at its San Antonio manufacturing facility in the third quarter of 2024. This significant achievement demonstrates the growth of the company's biomanufacturing capabilities, especially in the area of producing sophisticated biopharmaceuticals using mammalian cell culture.

Since Scorpius has already started cGMP activities in its microbiological facilities, the start of mammalian cGMP campaigns is a big step forward for the company's CDMO operations as it provides new income streams. Scorpius's specialised mammalian cell culture facility and cGMP-compliant controlled cleanrooms demonstrate the company's dedication to offering customised and flexible manufacturing solutions.

"I am extremely proud of what our team has accomplished in a short period of time," said Scorpius CEO Jeff Wolf. Our manufacturing and quality teams have put in a great deal of effort to have our mammalian facilities up and running in less than two years—much faster than is usually the case for such intricate buildouts. Today, Scorpius is in a very strong position to assist several early-stage clinical initiatives."

At Scorpius, our main goal is to give every customer the individualised care and methodical flexibility they merit. Cleanrooms with movable equipment are a feature of our facility's architecture, which makes it simple to alter layouts to suit the particular requirements of each project. Our approach involves broadening our range of offerings in tandem with our clients' program advancements through clinical research. As a sign of the need and confidence in our increased capabilities, Scorpius has already obtained reservations for more cGMP operations in the mammalian facility for 2025, Mr Wolf said.